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Methods: The OMV vaccine MenPF-1 was generated by genetically modifying N. meningitidis
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Results: MenPF-1 was safe and well tolerated. Immunogenicity was measured by serum bacte-
ricidal assay (SBA) against wild-type and isogenic mutant strains. After 3 doses, the proportion
of volunteers with SBA titres 1:4 (the putative protective titre) was 98% for the wild-type
strain, and 77% for the strain 44/76 FetAonPorAoff compared to 51% in the strain 44/76) 1865 857 485.
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FetA containing OMV vaccine: Immunogenicity in man 327FetAoffPorAoff, demonstrating that vaccination with MenPF-1 simultaneously induced FetA and
PorA bactericidal antibodies.
Conclusion: This study provides a proof-of-concept for generating bactericidal antibodies
against FetA after OMV vaccination in humans. Prevalence-based choice of PorA and FetA types
can be used to formulate a vaccine for broad protection against MenB disease.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Associat ion. This is an open access art icle under the CC BY l icense (http://
creativecommons.org/licenses/by/4.0/).Introduction
Capsular group B Neisseria meningitidis (MenB) is the pre-
dominant cause of invasive meningococcal disease (IMD)
in most European countries.1 In the USA, groups B, C and
Y cause IMD in similar proportions.2 Invasive MenB disease
has declined recently, but still caused 595/769 (77%) of
all cases of IMD in the UK in 2012/13,3 with an incidence
of 1.8/100,000 per year in the period 2006e2012.4 The
rapid onset of severe disease, potentially resulting in death
or significant disability, maintains MenB as a priority for
vaccine development. Successes with meningococcal A,
C,Y and W polysaccharideeprotein conjugate vaccines
have not been reproduced with MenB, perhaps due to anti-
genic similarity of group B capsule sialic acid and human
foetal neuronal cells, which is also a safety concern.5,6
This has led to the development of formulations based on
outer membrane vesicles (OMVs) containing PorA and other
outer membrane proteins.7 OMV vaccines have been shown
to be safe, to induce protective serosubtype (PorA)-specific
immune responses, and have been used to successfully con-
trol clonal outbreaks of MenB disease.8e14 However, these
vaccines offer limited protection against different serosub-
types (PorA types) of MenB. The vaccine 4CMenB, recently
licensed in Australia, Europe, Canada and the US, includes
an OMV component in addition to recombinant proteins15 to
induce protection against one PorA type.16
The PorA type-specificity of OMV vaccines occurs because
most bactericidal antibodies are directed against specific
surface-exposed epitopes on PorA, which are highly variable.
This means that multiple PorA types are required to cover
different strains.17e19 FetA is an additional vaccine candidate,
being a variable subcapsular antigen that has been shown to
induce bactericidal antibodies in animal models20e23 and to
acertainextentduringclinical trials,where immuneresponses
against FetA can be detected.21,24e26 As a consequence of
iron-dependent regulation of its expression during culture,27
the amount of FetA is variable in OMV vaccines, ranging from
0 to 9% of the total protein content of MenBVac and MeNZB,
used in Norway and New Zealand, respectively.28,29 FetA is a
TonB-coupled transporter, but its physiologically relevant sub-
strate is unclear: FetA from N.meningitidis has been shown to
bind ferric iron in vitro.30 Studies on FetA from Neisseria
gonorrhoeae have shown that it can transport a range of ferric
catecholate-type siderophores.31
Hyper-invasive lineages, those meningococcal genotypes
causing the majority of invasive disease, exhibit stable,
non-overlapping structures of their variable antigens, which
limits antigenic diversity.32 Analysis of the molecular epide-
miology of 4057 clinical IMD isolates obtained between 2000and 2002, across 18 European countries, revealed that 5/31
clonal complexes accounted for 77% of isolates.33,34 Eight
out of 273 PorA types accounted for 60% of isolates, and
6/99 FetA types accounted for 67% of isolates (Unpublished
results). Therefore, although these antigens are diverse,
only a few combinations of subtypes are responsible for
the majority of IMD and choice of a limited number of
PorA and FetA protein combinations based on surveillance
data has potential in designing a vaccine that harnesses
the immunogenicity of these proteins. As FetA immunoge-
nicity is less certain than PorA, which is immunodominant,
we aimed to demonstrate that constitutive expression of
FetA in an OMV vaccine simultaneously induces FetA and
PorA bactericidal responses, to provide a proof-of-concept
for a PorAeFetA vaccine. Such a vaccine could contain a
combination of several proteins that covers the majority
of global meningococcal disease. An OMV vaccine express-
ing a defined and consistent quantity of FetA was produced
to express a single PorA and a single FetA (MenPF-1). This
novel vaccine was tested in a phase I clinical trial to
examine safety, tolerability and immunogenicity in healthy
adults.Materials and methods
Molecular epidemiology and estimation of
hypothetical vaccine coverage
A vaccine recipe based on that from Russell et al.35 was
used to estimate potential coverage of a PorA/FetA vac-
cine based on meningococcal disease isolates collected
over a number of decades in England and Wales, which
had been characterised by PorA and FetA variable region
(VR) sequence typing. This included the 323 disease iso-
lates from 1975, 1985 and 1995,35 150 disease isolates
from England and Wales from the EUMenNet study34
(http://pubmlst.org/) and 1381 disease isolates from
the Meningitis Research Foundation Meningococcus
Genome Library (MRF MGL) (http://www.meningitis.org/
research/genome). The EUMenNet isolates were from
the years 2000e2002 inclusive and the MRF genome li-
brary ones were from the epidemiological years 07/
2010e06/2011 to 07/2012e06/2013 inclusive. Isolates
with an exact match to at least one of the five PorA
VR1, VR2 and FetA VRs were considered to be potentially
covered by the vaccine. The vaccine components were:
VR1: 5-1, 5, 7-2, 7, 19; VR2: 2-2, 2, 4, 15, 10; FetA VR:
F1-5, F3-6, F5-1, F3-9, F4-1. Estimated incidence of
meningococcal disease calculated from: 1912e1997
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IBIS report,36 2012 Health Protection Report37 and Gray
et al., 2006.38 Reporting criteria and methods have
changed on multiple occasions. England and Wales popu-
lation data was obtained from the Office for National Sta-
tistics (ONS) (http://www.ons.gov.uk/).
Ethics and approvals
Clinical Trial Authorisation was granted by the United
Kingdom Medicines and Healthcare products Regulatory
Agency (MHRA reference 21584/0298/001-0001). Ethical
approval and amendments were granted by NRES Oxford A
(12/SC/0023). The trial was registered with clinicaltrials.
gov and EudraCT (NCT01640652 and 2012-001046-17
respectively). The trial was conducted in accordance
with the clinical trial protocol and the principles of the
Declaration of Helsinki (2008) and the International Con-
ference on Harmonization (ICH) Good Clinical Practices
standards.
Vaccine construction and preparation
MenPF-1 was produced to Good Manufacturing Practice
(GMP) standard at the Norwegian Institute of Public Health
(NIPH) from a genetically modified 44/76 N. meningitidis
strain (PorA variant P1.7,16 and FetA variant F3-3), as
described for the Norwegian OMV vaccine.29,39 The wild-
type promoter region of the fetA gene was replaced with
a 17 bp spacer region derived from the promoter region
of porA, removing iron regulation of FetA expression and
ablating slipped strand mis-pairing; the result was a genet-
ically modified 44/76 strain with constitutive expression of
FetA and wild-type expression of PorA (unpublished data).
OMVs were obtained by detergent extraction, the vaccine
consisted of OMVs in sterile solution formulated with
aluminium hydroxide, 3% sucrose and water (unpublished
data). The vaccine contained 21.8% PorA and 7.7% FetA
(of total protein). To investigate whether the FetA levels
were abnormally high in the vaccine strain, making the
strain more susceptible to killing in the SBA assay, relative
to the natural isolate, QC data on the vaccine were
compared with existing data on iron-induced FetA expres-
sion in the wild-type strain. Frasch et al. reported that
wild-type 44/76 OMVs contain 0e10% FetA.29 The FetA con-
tent of dOMVs from the mutant strain was 7.7%, so the
expression in the mutant is within the capabilities of the
wild-type strain under certain growth conditions. PorA
(21.8% protein) is also within range of the wild-type. Vacci-
nation was with 0.5 ml vaccine for the 25 mg dose or 1.0 ml
for the 50 mg dose.
Phase I study design
The study was an open-label, dose-escalation, single-site,
phase I clinical trial in healthy adults. Three doses of 25 mg
or 50 mg MenPF-1 were given intra-muscularly 8 weeks
apart. Twenty six volunteers were assigned to each dosing
group by sequential allocation, and invited to attend 18
visits over 20 weeks (at 0 h, 4e6 h, 24 h, 7, 14 and 28 days
after each vaccination).Study participants and eligibility criteria
Male and female (using contraception) participants who
fulfilled all of the inclusion criteria were enrolled into the
trial. Inclusion criteria were ability to give informed con-
sent, aged between 18 and 50 years, in good health, able to
attend visits, willing to allow GP/consultant to be notified
of their involvement in the study and confirmation from
their GP that they were suitable for inclusion in the trial.
All volunteers provided informed consent in writing prior to
any study procedures. Volunteers were excluded if they had
any history of significant organ or system disease, known or
suspected alteration in immune function (including IgA
deficiency and autoimmune disease), previous receipt of a
MenB vaccine of any kind, previous disease caused by N.
meningitidis or any other significant disease or disorder
that presented potential for risk, could influence the re-
sults or impair the participants ability to participate in
the study.
Safety monitoring
Frequency and severity of solicited and unsolicited local
and systemic adverse events were monitored and reported
by study participants for one week after vaccination using
electronic diary cards. Adverse events were graded using
modified Food and Drug Administration (FDA) and Division
of AIDS (DAIDs) criteria (Tables S1 and S2). Volunteers were
observed for 1 h post vaccination for immediate adverse re-
actions. Full blood counts and differential serum renal and
liver biochemistry, C-reactive protein and amylase and visit
observations (pulse, respiratory rate, blood pressure) were
recorded at all visits. An independent data safety moni-
toring committee provided real-time safety oversight for
the duration of the trial, approved safety interpretation
and gave formal approval for dose-escalation.
Analysis of bactericidal responses by Serum
Bactericidal Assay (SBA)
Functional antibody responses were measured using SBA
with human complement, as previously described.40 The
SBA was performed on sera from all volunteers available
at baseline and after the first or second dose against several
bacterial target strains. The isogenic mutant 44/76 FetAon-
PorAon (SMenPF1.2) was the strain used to produce the
OMVs in the MenPF-1 vaccine, and the strains 44/76 FetAoff-
PorAoff, 44/76 FetAoffPorAon and 44/76 FetAonPorAoff were
created to assess the independent contributions of PorA
and FetA antibodies (Table 1). The level of expression of
PorA and FetA were measured on the modified strains by
SDS-PAGE, as SBA responses are likely to be affected by
expression levels.41 In the 2 strains constitutively express-
ing FetA (FetAon), there was similar amount of FetA, irre-
spective of whether PorA was on or off. Similarly, there
was a similar amount of PorA in the mutant strains express-
ing or not FetA. There were also similar amounts of other
components in all 4 mutant strains. Exogenous human com-
plement without intrinsic bactericidal activity was sourced
from consenting healthy adults and used at 25% (vol/vol)
with each target strain having a single complement source.
Table 1 Bacterial strains used in the Serum Bactericidal Assay.
Strain Genotype Study name PorA expression FetA expression
WT 44/76 (wild-type) 44/76 WT On Iron restricted
SMenPF1.2 44/76 fetAp17bp 44/76 FetAonPorAon On On
3043 44/76 fetA::kan 44/76 FetAoffPorAon On Off
3311 44/76 fetA::kan porA::ery 44/76 FetAoffPorAoff Off Off
3312 44/76 fetAp17bp porA::ery 44/76 FetAonPorAoff Off On
(WT) 44/76 (wild-type) with constitutive PorA expression and iron-dependent FetA expression. (SMenPF1.2) 44/76 fetAp17bp is derived
from the MenPF-1 GMO strain and constitutively expresses both PorA and FetA. (3043) 44/76 fetA::kan expression of FetA is interrupted
by kanamycin resistance gene insertion. (3311) 44/76 fetA::kan porA::ery kanamycin and erythromycin resistance gene insertions used
to interrupt FetA and PorA expression respectively. (3312) 44/76 fetAp17bp porA::ery constitutively expresses FetA with PorA expression
interrupted by insertion of erythromycin resistance gene.
Table 2 Components of Russell et al. PorA/FetA recipe in
Fig. 1.
Recipe FetA VR VR1 VR2
1 component F1-5 5-1 2-2
2 components F1-5 5-1 2-2
F3-6 5 2
3 components F1-5 5-1 2-2
F3-6 5 2
F5-1 7-2 4
4 components F1-5 5-1 2-2
F3-6 5 2
F5-1 7-2 4
F3-9 7 15
5 componentsa F1-5 5-1 2-2
F3-6 5 2
F5-1 7-2 4
F3-9 7 15
F4-1 19 10
a The 5PorA/FetA vaccine recipe used to determine theoret-
ical amount of disease incidence prevented/present if PorA/
FetA vaccine recipe was applied to meningococcal disease inci-
dence in England and Wales 1975e2012.
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were stored at 80 C prior to heat inactivation at 56 C for
30 min. Bacterial strains were grown overnight on blood
agar plates at 37 C and 5% CO2. Approximately 50 colonies
were sub-cultured for 4 h, reconstituted in Hanks buffered
salt solution (Gibco) with 0.5% bovine serum albumin (Sigma
Aldrich). The bacteria were diluted to give approximately
100 colony forming units per 10 ml used for the assay. The
SBA titre was defined as the reciprocal of the highest dilu-
tion of serum that yielded 50% decrease in colony forming
units relative to that of control wells within 60 min at 37 C.
Statistics
The sample size of each cohort is comparable to studies of
other capsular group B OMV vaccines that assessed the
safety and tolerability of three doses in healthy adult
volunteers.42 All available data were used and presented
according to the assigned dose group. Analyses for the pri-
mary endpoints were descriptively summarised. Severity
and number of days for each adverse systemic or local reac-
tion was presented as counts and proportions or percent-
ages per dose groups, with 95% CI calculated using the
binomial exact method. Missing e-diary reported data
were assumed to correspond to no symptoms on that day.
No formal hypothesis tests were carried out. Immunological
data were, where appropriate, log10-transformed prior to
analyses, and back-transformed to be presented as geomet-
ric means with 95% confidence intervals according to each
time point and group. Missing data due to laboratory pro-
cessing issues were considered as missing completely at
random. Statistical analyses were performed using STATA
version 13.1 (StataCorp LP, Texas, USA) and SAS version
9.3 (SAS Institute, Cary, NC, USA).
Results
Molecular epidemiology-based design of the
vaccine
A hypothetical vaccine containing a combination of five
PorA and five FetA proteins (5PorAeFetA) (Table 2) could in
principle have conferred protection against 83e93% of
cases of IMD in England and Wales between the period
1975 and 2002 (Fig. 1A). After 2002, potential coverage ofthis 5PorAeFetA recipe reduced to 68%, which is a conse-
quence of natural fluctuations in meningococcal types.
We modelled an impact of the 5PorAeFetA vaccine using
incidence data from between 1975 and 2012 (Fig. 1B) and
found that a 5-valent vaccine with 100% efficacy would
have reduced invasive disease incidence to below 0.5/
100,000 across this period. This compares with the actual
incidence in 1985 and 1995 of 1.10 and 3.61/100,000
respectively. This retrospective analysis demonstrates the
potential impact of PorA and FetA multicomponent vac-
cines on disease rates in recent decades. This vaccine
design is based on the contention that a vaccine containing
both PorA and FetA antigens induces simultaneous FetA and
PorA bactericidal responses in humans. To test this, an OMV
vaccine expressing a defined and consistent quantity of
FetA was produced to express a single PorA and a single
FetA (MenPF-1). This novel vaccine was tested in a phase
I clinical trial to examine safety, tolerability and immuno-
genicity in healthy adults.
Figure 1 A vaccine recipe (5PorAeFetA) based on that from Russell et al., 200835 was used to estimate potential coverage
and longevity of a PorA/FetA based recipe over a number of decades in England and Wales. (A) Potential coverage of PorA/FetA
recipes35 in England and Wales 1975e1995, 2000e2002 and 2010e2013 dataset with increasing number of components (PorA var-
iable regions e VRs). (B) Theoretical amount of disease incidence prevented/present if 5PorA/FetA recipe was implemented in En-
gland and Wales 1975e2012. Isolates with an exact match to at least one of the five PorA VR1, VR2 and FetA VRs were considered to
be covered by the recipe.
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Recruitment commenced in October 2012; 75 volunteers
were assessed by the trial physicians and 52 were enrolled.
The final clinical trial data were collected one month after
the last vaccine dose (June 2013). Recruitment, enrolment
and withdrawals are presented in Fig. 2. Overall, 856/872
(98.2%) of all attended visits were performed within the
protocol-defined window after vaccination. The baseline
physical and demographic characteristics of enrolled volun-
teers are presented in Table 3.Safety of MenPF-1 in healthy adults
There were no serious adverse events, serious adverse
reactions, severe unexpected serious adverse reactions or
medically significant adverse events. Adverse events to
vaccination were mostly local reactions at the site of
injection, mild to moderate in severity and transient self-
limiting reactions that lasted only a few days (Table 4).
There was no evidence of cumulative adverse event fre-
quency or severity with repeated doses of vaccine and sys-
temic symptoms such as fever were infrequent (Table 4).
Visit observations and safety blood testing did not show
any safety concerns (data not shown).Serum bactericidal antibody responses are induced
against homologous wild-type strain 44/76
Baseline sera were available for all participants, 46/52 at
four weeks after the second dose and 47/52 at four weeks
post third dose. The majority of volunteers developed an
SBA titre 1:4 against the homologous 44/76 WT strain
after 3 doses in both the 25 mg (95%) and 50 mg dose groups
(100%) (Fig. 3A), as compared to 42% and 43%, respectively,
at baseline. The baseline geometric mean titres (GMTs)
were 4.8 and 3.5 in participants receiving 25 mg and 50 mg
doses respectively, indicating low levels of naturally ac-
quired SBA activity in most volunteers prior to vaccination.
After 3 doses of MenPF-1 the GMTs increased to 24.0 and
31.1 in the low and high dose groups respectively
(Table 5). The study was not powered to investigate
whether there was significant differences between 2 or 3
doses or between the 25 or 50 mg doses.
MenPF-1 induced PorA-specific serum bactericidal
antibodies as expected
Isogenic target strains were used to investigate the relative
contributions of FetA and PorA antibodies towards bacte-
ricidal activity following MenPF-1 vaccination. The
Figure 2 Flow diagram for recruitment, enrolment and completion of trial. Withdrawals were not related to the study vaccine
and all new and medically relevant information that was detected at screening were communicated to the candidate volunteers’
General Practitioners with their permission.
Table 3 Baseline physical and demographic characteristics of study volunteers enrolled.
25 mg dose group 50 mg dose group
N enrolled Dose 1 26 26
Dose 2 23 25
Dose 3 22 25
Median age at enrolment, years (minemax) 30 (19e49) 24 (18e44)
Male (%) 17 (65.4) 10 (38.5)
Ethnicity by count White British 23 16
White (Other) 1 7
White (Irish) 0 1
Pakistani 1 0
Chinese 1 0
Black (Other) 0 1
Mixed 0 1
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Table 4 Frequency of volunteer reported solicited adverse events within one week of each dose of vaccine, presented by severity grade.
Solicited symptoms within one week Dose 1 Dose 2 Dose 3
n Any (%) Mild (%) Mod (%) Sev (%) n Any (%) Mild (%) Mod (%) Sev (%) n Any (%) Mild (%) Mod (%) Sev (%)
Tenderness/pain at the site of
injection
25 mg dose 25 21 (84) 15 (60) 6 (24) 0 (0) 22 21 (95) 17 (77) 3 (14) 1 (5) 21 20 (95) 14 (67) 3 (14) 3 (14)
50 mg dose 26 25 (96) 10 (39) 13 (50) 2 (8) 23 23 (100) 12 (52) 9 (39) 2 (9) 24 22 (92) 12 (50) 7 (29) 3 13)
Headache 25 mg dose 24 4 (17) 3 (13) 1 (4) 0 (0) 22 9 (41) 6 (27) 3 14) 0 (0) 21 7 (33) 6 (29) 1 (5) 0 (0)
50 mg dose 26 12 (46) 8 (31) 4 (15) 0 (0) 23 7 (30) 4 (17) 2 (9) 1 (4) 23 7 (30) 3 (13) 3 (13) 1 (4)
Malaise 25 mg dose 24 4 (17) 3 (13) 0 (0) 1 (4) 22 6 (27) 5 (23) 1 (5) 0 (0) 21 5 (24) 2 (10) 2 (10) 1 (5)
50 mg dose 26 10 (38) 9 (35) 1 (4) 0 (0) 23 7 (30) 3 (13) 4 (17) 0 (0) 23 8 (35) 5 (22) 3 (13) 0 (0)
Myalgia 25 mg dose 24 10 (42) 8 (33) 2 (8) 0 (0) 22 9 (41) 9 (41) 0 (0) 0 (0) 21 11 (52) 7 (33) 3 (14) 1 (5)
50 mg dose 26 13 (50) 8 (31) 4 (16) 1(4) 23 10 (43) 7 (30) 2 (9) 1 (4) 23 11 (48) 8 (35) 3 (13) 0 (0)
Nausea and/or vomiting 25 mg dose 24 1 (4) 0 (0) 0 (0) 1 (4) 22 1 (5) 1 (5) 0 (0) 0 (0) 21 5 (24) 3 (14) 1 (5) 1 (5)
50 mg dose 26 2 (8) 2 (8) 0 (0) 0 (0) 23 4 (17) 3 (13) 1 (5) 0 (0) 23 2 (9) 2 (9) 0 (0) 0 (0)
Arthralgia 25 mg dose 24 1 (4) 1 (4) 0 (0) 0 (0) 22 4 (18) 4 (18) 0 (0) 0 (0) 21 4 (19) 3 (15) 1 (5) 0 (0)
50 mg dose 26 5 (19) 3 (12) 2 (8) 0 (0) 23 3 (13) 2 (9) 0 (0) 1 (4) 23 5 (22) 4 (17) 1 (5) 0 (0)
Oral temperature (fever) 25 mg dose 25 0 (0) 0 (0) 0 (0) 0 (0) 22 1 (5) 0 (0) 1 (5) 0 (0) 21 1 (5) 0 (0) 1 (5) 0 (0)
50 mg dose 26 0 (0) 0 (0) 0 (0) 0 (0) 23 0 (0) 0 (0) 0 (0) 0 (0) 24 0 (0) 0 (0) 0 (0) 0 (0)
Redness at the site of injection 25 mg dose 25 19 (76) 18 (72) 0 (0) 1 (4) 22 20 (91) 20 (91) 0 (0) 0 (0) 21 19 (90) 17 (81) 0 (0) 2 (10)
50 mg dose 26 21 (81) 19 (73) 1 (4) 1 (4) 23 21 (91) 18 (78) 0 (0) 3 (13) 24 23 (96) 22 (92) 0 (0) 1 (4)
Induration at the site of
injection
25 mg dose 25 11 (44) 11 (44) 0 (0) 0 (0) 22 15 (68) 15 (68) 0 (0) 0 (0) 21 11 (52) 11 (53) 0 (0) 0 (0)
50 mg dose 26 17 (65) 15 (58) 0 (0) 2 (8) 23 19 (83) 17 (74) 1 (4) 1 (4) 24 13 (54) 12 (50) 0 (0) 1 (4)
Swelling at the site of injection 25 mg dose 25 10 (40) 8 (32) 0 (0) 2 (8) 22 11 (50) 8 (36) 0 (0) 3 (14) 21 11 (52) 9 (43) 1 (5) 1 (5)
50 mg dose 26 10 (38) 8 (31) 0 (0) 2 (8) 23 16 (70) 13 (57) 0 (0) 3 (13) 24 17 (71) 14 (58) 1 (4) 2 (8)
Volunteers reported symptoms as mild (does not interfere with routine activities), moderate (interferes with routine activities) and severe (unable to perform routine activities). Redness,
swelling and induration at the site of injection used the maximal recorded diameter of any reaction for severity grading as mild (1e10 mm), moderate (11e25 mm) and severe (26 mm).
Oral temperature was graded as mild (38.0e38.4 C), moderate (38.5e38.9 C) and severe (39.0 C).
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Figure 3 Percentage of participants that had an SBA titre ‡1:4 at baseline and 4 weeks after 2 or 3 doses of MenPF-1. Per-
centage of participants with an SBA titre 1:4 as main bars (with 95% CI error bars) for participants receiving 25 mg of vaccine (lines)
and 50 mg of vaccine (dark solid) at baseline and 4 weeks after 2 or 3 doses of MenPF-1. SBA titres were determined as the reciprocal
dilution where bacterial survival was less than 50% of that of controls for the parental wild-type strain 44/76 (A), 44/76 FetAoff-
PorAoff (B), 44/76 FetAoffPorAon (C), 44/76 FetAonPorAoff (D) and 44/76 FetAonPorAon (E).
FetA containing OMV vaccine: Immunogenicity in man 333proportion of volunteers with baseline SBA activity 1:4
against the target strain 44/76 FetAoffPorAoff were 35% and
28% in the 25 mg and 50 mg dose groups respectively,
increasing to 41% and 60% respectively after 3 doses of
MenPF-1 (Fig. 3B). The proportion of responders to the
isogenic strain 44/76 FetAoffPorAon were 39% and 32% in
the 25 mg and 50 mg dose groups respectively at baseline,
increasing to 91% and 96% after 3 doses (Fig. 3C). The
GMT values after 3 doses against the strain 44/76 FetAoff-
PorAoff were 3.6 (95% CI 2.5, 5.4) and 6.6 (95% CI 3.6,
11.9) in the 25 mg and 50 mg dose groups respectively, as
compared to 19.9 (95% CI 9.9, 40.1) and 29.4 (95% CI
16.4, 52.9) against 44/76 FetAoffPorAon (Table 5). TheseTable 5 SBA geometric mean titres at baseline and 4 weeks af
Strain SBA GMTs (95% CI)
25 mg dose
Baseline After 2 doses After 3 d
44/76 WT 4.8 (2.9, 7.9) 17.0 (9.2, 31.5) 24.1 (12
44/76 FetAonPorAon 6.3 (3.7, 10.7) 21.2 (12.1, 37.4) 30.0 (15
44/76 FetAoffPorAon 4.2 (2.6, 6.8) 14.6 (7.7, 27.6) 19.9 (9.
44/76 FetAoffPorAoff 3.2 (2.3, 4.6) 4.3 (2.8, 6.4) 3.6 (2.
44/76 FetAonPorAoff 4.5 (2.7, 7.6) 4.7 (3.0, 7.3) 7.3 (4.results demonstrate that a PorA-specific bactericidal
response was induced in most participants.
MenPF-1 induced FetA-specific serum bactericidal
antibodies
Most importantly, the isogenic strain 44/76 FetAonPorAoff
was designed to quantify the FetA-specific bactericidal
response. The proportion of responders with SBA activity
1:4 against this strain were 39% (25 mg dose) and 32%
(50 mg) at baseline compared to 73% and 80% after 3 doses
of MenPF-1 (Fig. 3D). The proportion of responders was
greater against 44/76 FetAonPorAoff than was observedter 2 or 3 doses of MenPF-1 (95% CI).
50 mg dose
oses Baseline After 2 doses After 3 doses
.3, 47.3) 3.5 (2.4, 5.0) 23.0 (12.1, 43.8) 31.1 (19.2, 50.5)
.7, 57.5) 2.2 (2.8, 6.4) 42.7 (23.1, 79.1) 49.9 (29.8, 83.5)
9, 40.1) 3.0 (2.3, 4.0) 26.1 (12.8, 53.4) 29.4 (16.4, 52.9)
5, 5.4) 2.5 (2.2, 2.9) 4.8 (3.0, 7.8) 6.6 (3.6, 11.9)
6, 11.6) 3.1 (2.3, 4.3) 7.6 (4.4, 12.9) 11.2 (6.5, 19.2)
334 L. Marsay et al.against strain 44/76 FetAoffPorAoff, which lacks expression
of FetA (Fig. 3B). The GMTs were also greater against 44/
76 FetAonPorAoff than 44/76 FetAoffPorAoff in both the
25 mg and 50 mg dose groups after 3 doses, with values of
7.3 (95% CI 4.6, 11.6) and 11.2 (95% CI 6.5, 19.2) respec-
tively, vs. 3.6 (95% CI 2.5, 5.4) and 6.6 (95% CI 3.6, 11.9).
These results indicate that MenPF-1 was able to induce
FetA-specific bactericidal antibodies.
In addition, when 44/76 FetAonPorAon (vaccine strain)
was the target strain for SBA, the proportion of baseline re-
sponders with titres 1:4 was 57% in the 25 mg dose group
and 40% in the 50 mg dose group (Fig. 3E), increasing to
96% and 100% after 3 doses of MenPF-1. In both the 25 mg
and 50 mg dose groups the GMTs against 44/76 FetAonPorAon
were higher than those detected against the FetAoffPorAon
strain, where FetA expression is absent. The GMTs in the
high dose group were 4.2 (95% CI 2.8, 6.4), 42.7 (95% CI
23.1, 79.1) and 49.9 (95% CI 29.8, 83.5) at baseline, after
2 and 3 doses respectively, as compared to the FetAoffPor-
Aon strain where GMTs of 3.0 (95% CI 2.3, 4.0), 26.1 (95% CI
12.8, 53.4) and 29.4 (95% CI 16.4, 52.9) were observed
respectively. This result suggests that FetA-specific bacteri-
cidal antibodies generated in response to MenPF-1 were ad-
ditive to the PorA-specific SBA responses.Discussion
We demonstrated that immunisation with OMVs derived
from a meningococcal strain that constitutively expressed
FetA elicited both PorA and FetA-specific bactericidal
antibodies in humans, providing evidence that a multicom-
ponent vaccine based on PorA and FetA could be used to
provide protection against meningococcal disease. In order
to assess the contribution of FetA bactericidal antibodies,
SBA assays were conducted targeting isogenic strains in
which the level of FetA expression was measured.41 Immu-
nisation with MenPF-1 led to elevated GMTs in SBA against
the target strain 44/76 FetAonPorAon in comparison to
wild-type 44/76. Furthermore, the bactericidal activity
against 44/76 FetAonPorAoff indicated a FetA-specific
response, which was greater at the last time-point, illus-
trating the benefit of the third dose. While immune re-
sponses against FetA have been observed in convalescent
patients after meningococcal disease,43 the present trial
demonstrates that such bactericidal activity can be induced
against the antigen through vaccination with OMVs.
In addition to being immunogenic in healthy adults
MenPF1 was safe. The greater reporting of pain and
tenderness at the site of injection from volunteers who
received 50 mg may be a true dose effect or a confounding
observation due to doubling the vaccine volume (to 1 ml)
and/or doubling the quantity of adjuvant, which was
necessary in this study for dose escalation. Missing solicited
symptom data were assumed to correspond to no symptoms
on that day; however, these missing data accounted for
only 634/10,291 (6.2%) of solicited symptom data points.
Overall the side effects reported in this trial are compara-
ble to those observed following use of other OMV MenB
vaccines in healthy adults.7 The low frequency of fever is in
contrast to infant fever previously observed with 25 mg dose
OMV vaccines44 possibly due to an age-specific effect.Adverse events were also reported in adults following vacci-
nation with 4CMenB, a multicomponent MenB vaccine con-
taining the same OMV as MeNZB,45 although this is not
directly comparable because it also contains three recom-
binant proteins, which may contribute to reactogenicity.
We have confirmed the immunogenicity of the MenPF-1
formulation against the homologous vaccine strain as well
as the wild-type and isogenic strains. While it is known that
SBA titres tend to differ amongst laboratories,46 the titres
against 44/76 in adults immunised with three 25 mg doses
of MenBVac were comparable to those recorded for the
low dose group in the present study46 and the titres seen af-
ter 3 50 mg doses of MenPF-1 were similar to those seen
against strain NZ98/294 in adults vaccinated with 3 doses
of 4CMenB.47 As was seen for MenBVac,46 participants im-
munised with MenPF-1 demonstrated an increase in func-
tional antibodies against 44/76 after the second and third
doses. A considerable proportion of the increase in func-
tional antibodies was directed against PorA as demon-
strated by the lower GMTs detected against the isogenic
strains with PorA expression removed. The induction of
PorA-specific functional responses is in agreement with pre-
vious capsular group B OMV vaccine trials.48 As an immuno-
dominant antigen in the meningococcus, PorA responses
account for a large proportion of detected bactericidal an-
tibodies against homologous target strains. Coupled with
this, P1.7,16 has been consistently shown to be more immu-
nogenic than other PorA variants48e50 and was expected to
play a major role in inducing bactericidal activity in this
study. The relative immunogenicity of different FetA types
have not yet been determined and could also be variable.
The baseline levels of anti-FetA and PorA bactericidal
activity are probably attributable to prior natural exposure
to circulating strains of N. meningitidis. Meningococci of
the ST-32 complex were found in 6.5% of IMD isolates in En-
gland and Wales between 2006 and 2009.51 The PorAeFetA
combination in the current study is common amongst the
ST-32 complex organisms.52 While not characterised in the
current study, there are a number of other antigens that
may have contributed to the immunogenicity of MenPF-1.
Relatively high pre-vaccination levels of SBA against 44/76
FetAoffPorAoff demonstrate that a considerable proportion
of subjects had functional antibodies against a number of
non-PorA or FetA antigens, which increased after MenPF-1
vaccination. Some minor antigens have been identified pre-
viously using OMV vaccines including TbpA, Hsf and NspA.53
While both PorA and FetA-specific bactericidal responses
were induced, the latter was possibly limited by the
expression level of FetA (around 7%), in comparison to
PorA (21.8%). Therefore, given the potential for inducing
FetA specific antibodies, future improvements would
include enhanced expression of FetA. Furthermore, OMV
vaccine-induced bactericidal antibodies to PorA variant
P1.7,16 show very limited cross-reactivity against heterol-
ogous variants,19,48 thus this single-strain OMV vaccine
would not confer broad protection against diverse MenB
disease. Therefore, future studies will focus on combining
and evaluating the response to PorA and FetA variants cho-
sen to broaden the coverage of epidemiologically relevant
MenB strains. As PorA and FetA data are used as part of
the routine surveillance of meningococcal disease across
many reference labs, changes associated with IMD could
FetA containing OMV vaccine: Immunogenicity in man 335be used to inform PorA/FetA vaccine combinations to main-
tain optimal coverage. In addition, such a vaccine would
not be based on the bacterial capsule, so could potentially
protect against meningococci expressing other capsular
groups.
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